


Intepirdine

Cat. No.:	HY-14339		
CAS No.:	607742-69-8		
Molecular Formula:	C ₁₉ H ₁₉ N ₃ O ₂ S		
Molecular Weight:	353.44		
Target:	5-HT Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (141.47 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.8293 mL	14.1467 mL	28.2933 mL
		5 mM		0.5659 mL	2.8293 mL	5.6587 mL
		10 mM		0.2829 mL	1.4147 mL	2.8293 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Intepirdine (SB742457) is a highly selective 5-HT ₆ receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.
IC ₅₀ & Target	5-HT ₆ Receptor 9.63 (pKi)
In Vitro	Intepirdine (SB742457), a 5-HT ₆ receptor antagonist, which extends into Alzheimer disease (AD) sufferers further highlights the therapeutic promise of this mechanistic approach. Alzheimer's disease is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. With the subsequent development of selective 5-HT ₆ receptor antagonists, preclinical

studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT₆ receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. Intepirdine (SB742457) is generally safe and well tolerated and may be efficacious in Alzheimer disease.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Protein Cell. 2019 Mar;10(3):178-195.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Callaghan CK, Hok V, Della-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT₆ receptor antagonist SB742457. *Neuropharmacology*. 2012 Oct;63(5):890-7.
- [2]. Codony X, Vela JM, Ramírez MJ. 5-HT₆ receptor and cognition. *Curr Opin Pharmacol*. 2011 Feb;11(1):94-100.
- [3]. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. *Int J Geriatr Psychiatry*. 2011 May;26(5):536-44.
- [4]. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT₆ receptor antagonist, SB-742457, in Alzheimer's disease. *Curr Alzheimer Res*. 2010 Aug;7(5):374-85.
- [5]. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT₆ receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. *Neurotherapeutics*. 2008 Jul;5(3):458-69.
- [6]. SB-742457
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA